Christian Hansen CHR

COP: CHR | ISIN: DK0060227585   30/01/2024
549,60 DKK (-0,61%)
(-0,61%)   30/01/2024

29 januari 2024 · Completion of the combination between Novozymes and Chr. Hansen · Persbericht

26 januari 2024 · All necessary regulatory approvals have been obtained for the combination of Novozymes and Chr. Hansen · Persbericht

20 december 2023 · Update on the merger approval process for the combination of Novozymes and Chr. Hansen: South Korean merger approval granted · Persbericht

19 december 2023 · Major shareholder announcement from Burlington Loan Management DAC · Persbericht

12 december 2023 · Update on the merger approval process for the combination of Novozymes and Chr. Hansen: Conditional competition clearance from the European Commission obtained · Persbericht

20 november 2023 · Update on the merger approval process for the combination of Novozymes and Chr. Hansen: The parties have submitted a remedy proposal to the European Commission. · Persbericht

2 november 2023 · Managers' Transaction · Persbericht

13 oktober 2023 · Managers' Transactions · Persbericht

12 oktober 2023 · Chr. Hansen Holding A/S Interim Report Q4 2022/23 · Persbericht

10 oktober 2023 · Novozymes announce the Executive Leadership Team and organizational structure for the future combined company of Novozymes and Chr. Hansen · Persbericht

27 september 2023 · Major shareholder announcements from Burlington Loan Management DAC and Davidson Kempner Capital Management LP · Persbericht

4 september 2023 · Update on the combination of Novozymes and Chr. Hansen: Chinese merger approval granted, supporting the path to completion · Persbericht

6 juli 2023 · Chr. Hansen Holding A/S Interim Report Q3 2022/23 · Persbericht

13 april 2023 · Chr. Hansen Holding A/S Interim Report Q2 2022/23 · Persbericht

30 maart 2023 · Novozymes’ and Chr. Hansen’s shareholders approve combination to create a leading global biosolutions partner · Persbericht

30 maart 2023 · Resolutions passed at the Extraordinary General Meeting of Chr. Hansen Holding A/S · Persbericht

30 maart 2023 · Combination between Novozymes and Chr. Hansen approved by Novozymes’ shareholders · Persbericht

28 maart 2023 · Update on the combination of Novozymes and Chr. Hansen: U.S. antitrust regulation waiting period has expired, supporting the path to completion · Persbericht

8 maart 2023 · Notice to convene Extraordinary General Meeting · Persbericht

8 maart 2023 · Publication of exemption document in relation to the proposed combination of Chr. Hansen and Novozymes, confirmation of outlook for 2022/23 and proposed candidates to the Board of Directors of the combined company · Persbericht

Mijn selecties